DoW Toxic Exposures Clinical Trial Award

Status

Open

Agency

Defense · DOD-AMRAA

Notice

HT942526TERPCTA

Type

Grant / cooperative agreement

Value

Total program funding: $4,500,000

Deadline

Nov 19, 2026 · confirm cutoff time in notice

Eligibility

Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled "Additional Information on Eligibility"

From the official notice

Summary: The fiscal year 2026 (FY26) Toxic Exposures Research Program (TERP) Clinical Trial Award (CTA) mechanism supports the advancement, execution, and analysis of clinical trials with the potential to have a significant impact on the prevention, treatment, or management of symptoms, diseases or conditions associated with or resulting from military-related toxic exposures. Proposed projects may range from small proof-of-concept clinical trials (e.g., pilot, first-in-human, phase 0) designed to demonstrate the feasibility or inform the design of more advanced trials, through large-scale trials (including pragmatic clinical trials) to determine efficacy in relevant patient populations. Distinctive Features: To encourage applications that include meaningful and productive collaborations, the FY26 TERP CTA includes a Partnering Principal Investigator Option (PPIO) . One Principal…

Source and next steps

Read the official notice and response instructions

This is a sourced opportunity notice. The summary is an excerpt from the issuing agency; amounts and eligibility are taken from its structured record. Check the full notice, amendments and submission requirements before responding.

Source observed 2026-10-23 Eastern. Browse opportunities